A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
Public ClinicalTrials.gov record NCT01673386. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-Blind, Crossover, Controlled, Multi-Center Subject Preference Study of Tivozanib Hydrochloride Versus Sunitinib in the Treatment of Subjects With Metastatic Renal Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Randomized, double-blind, 2-arm crossover study comparing tivozanib hydrochloride and sunitinib in subjects with metastatic RCC who have received no prior systemic therapy for Renal Cell Carcinoma (RCC).
Study identification
- NCT ID
- NCT01673386
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 58 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2012 (Type not available)
- Primary completion
- Jan 2014 (Actual)
- Completion
- Jan 2014 (Actual)
- Last update posted
- Oct 27, 2020
2012 – 2014
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Los Angeles | California | 90001 | — |
| Not listed | Albany | Georgia | 31701 | — |
| Not listed | Atlanta | Georgia | 30301 | — |
| Not listed | Chicago | Illinois | 60007 | — |
| Not listed | Indianapolis | Indiana | 46077 | — |
| Not listed | Shreveport | Louisiana | 71101 | — |
| Not listed | Worcester | Massachusetts | 01601 | — |
| Not listed | Minneapolis | Minnesota | 55111 | — |
| Not listed | New York | New York | 10001 | — |
| Not listed | Columbus | Ohio | 43004 | — |
| Not listed | Portland | Oregon | 97035 | — |
| Not listed | Charleston | South Carolina | 29401 | — |
| Not listed | Myrtle Beach | South Carolina | 29572 | — |
| Not listed | San Antonio | Texas | 78006 | — |
| Not listed | Madison | Wisconsin | 53558 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01673386, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 27, 2020 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01673386 live on ClinicalTrials.gov.